For example, preclinical studies have demonstrated that the enhanced expression of ASCT2 in response to androgen treatment results in the increased uptake of the synthetic leucine analogue fluciclovine (FACBC) into LNCaP cells.96,97 Furthermore, in clinical trials, fluciclovine was not only useful for localising recurrent prostate cancer but also for extra-prostatic metastases.96 Ongoing research to define AR-mediated amino acid dependencies in prostate cancer might lead to new prospects in the therapeutic field. This evidence concerns the gene SLC1A5 and prostate cancer.